Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunotherapy
Institute of Hematology and Blood Transfusion details research in immunotherapy
April 7th, 2009
A report, 'Combined chemo- and immunotherapy of tumors induced in mice by bcr-abl-transformed cells,' is newly published data in Oncology Reports. "For our experiments we selected two oncogenic, bcr-abl-transformed mouse cell lines, viz. B210 and 12B1. Both cell types are capable of inducing leukemia-like disease in syngeneic BALB/c mice after intravenous inoculation. 12B1 cells can moreover form solid tumors after subcutaneous injection," researchers in Praha, Czech Republic report. "Since immunotherapy would expectedly be most effective in animals in which the tumor mass had been reduced by other therapeutic means, we attempted to develop a combined therapeutic...
Source: Cancer Weekly (2009-04-07)
|
